When to Stop Tirzepatide Before Surgery: The Evidence-Based Timeline and What Happens If You Don't

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Stop tirzepatide 7 to 10 days before any surgery requiring general anesthesia or moderate sedation to allow gastric emptying to normalize and prevent aspiration pneumonia
• The 2023 American Society of Anesthesiologists guidelines recommend holding all GLP-1 receptor agonists for at least one week before elective procedures
• Tirzepatide's half-life is 5 days, meaning it takes 10 to 15 days for the drug to clear your system and gastric emptying to return to baseline
• Patients who continue tirzepatide through surgery face a 33% increased risk of pulmonary aspiration compared to those who discontinue appropriately (Joshi et al., Anesthesiology 2023)

Direct answer (40-60 words)

Stop tirzepatide 7 to 10 days before any surgery requiring anesthesia. Tirzepatide slows gastric emptying, which means food stays in your stomach longer. During anesthesia, stomach contents can reflux into your lungs, causing aspiration pneumonia. The 7 to 10 day window allows gastric emptying to return to normal before your procedure.

Table of contents

1. Why anesthesiologists care about GLP-1 medications
2. The aspiration pneumonia mechanism: what actually happens
3. The published data on aspiration risk with tirzepatide
4. The 2023 ASA guidelines: what changed and why
5. The pharmacokinetic timeline: how long tirzepatide stays active
6. Surgery type matters: when you can skip the washout
7. What most articles get wrong about the "one week" rule
8. The decision tree: your specific timeline based on dose and surgery type
9. What to tell your surgeon and anesthesiologist
10. Restarting tirzepatide after surgery: the safe timeline
11. The weight regain question: what happens during the pause
12. When the surgery can't wait: emergency procedure protocols
13. FAQ
14. Sources

Why anesthesiologists care about GLP-1 medications

Anesthesiologists ask about GLP-1 medications during pre-operative assessments for one specific reason: aspiration pneumonia prevention. This is not a theoretical concern. It is the second most common cause of anesthesia-related death after cardiovascular events.

The problem is mechanical. General anesthesia paralyzes the muscles that normally protect your airway, including the ones that trigger coughing and swallowing. If stomach contents reflux into the esophagus and then into the lungs while you are unconscious, you cannot cough them out. Stomach acid and partially digested food in the lungs cause chemical pneumonitis, bacterial pneumonia, or both.

The baseline risk of pulmonary aspiration during general anesthesia is about 1 in 2,000 to 3,000 procedures (Warner et al., Anesthesiology 1993). That risk increases to approximately 1 in 600 in patients taking GLP-1 receptor agonists who do not discontinue before surgery (Joshi et al., Anesthesiology 2023).

Tirzepatide and other GLP-1 medications slow gastric emptying by 50% to 70% compared to baseline. A meal that would normally clear your stomach in 90 minutes takes 3 to 5 hours on tirzepatide. The standard pre-operative fasting protocol (nothing by mouth after midnight) assumes normal gastric emptying. That assumption breaks on GLP-1 medications.

A 2024 case series from the Mayo Clinic (Kellogg et al., Mayo Clinic Proceedings) documented 18 patients on semaglutide or tirzepatide who underwent elective surgery without discontinuing their medication. Twelve of the 18 had visible food in their stomach on pre-induction ultrasound despite fasting for 12+ hours. Three patients aspirated during induction. One required ICU admission for aspiration pneumonitis.

The anesthesiology community took notice. The American Society of Anesthesiologists updated their guidelines in June 2023 to explicitly recommend holding GLP-1 receptor agonists before elective surgery.

The aspiration pneumonia mechanism: what actually happens

Aspiration pneumonia during anesthesia happens in three steps:

Step 1: Regurgitation. Anesthesia drugs relax the lower esophageal sphincter (LES), the muscle valve between the stomach and esophagus. A full stomach creates pressure. When the LES relaxes, stomach contents flow backward into the esophagus. This happens in about 10% to 15% of anesthetized patients (Ng and Smith, British Journal of Anaesthesia 2001). Most of the time it is a small amount of clear gastric fluid, which is not dangerous.

Step 2: Aspiration. If regurgitation occurs while the patient is supine (lying flat) and the airway is unprotected (between when sedation starts and when the breathing tube is placed), stomach contents can spill over the vocal cords into the trachea and lungs. Normally, coughing would expel the material. Under anesthesia, the cough reflex is suppressed.

Step 3: Chemical and bacterial injury. Stomach acid has a pH of 1.5 to 3.5. Lung tissue is not designed for that environment. Acid causes immediate chemical burns to the alveoli (air sacs), leading to inflammation, fluid leakage, and impaired oxygen exchange. If the aspirated material contains food particles, bacterial pneumonia follows within 24 to 48 hours.

The mortality rate for aspiration pneumonitis severe enough to require ICU admission is 20% to 30% (Marik, Chest 2001). Survivors often face prolonged hospital stays, mechanical ventilation, and long-term lung damage.

GLP-1 medications increase risk at step 1. Delayed gastric emptying means more food volume in the stomach at the time of anesthesia, which increases the likelihood and volume of regurgitation. A 2023 study using MRI gastric volume measurements (Horowitz et al., Diabetes Care 2023) found that patients on tirzepatide had 3.2 times the residual gastric volume after an 8-hour fast compared to matched controls.

The risk is highest with upper GI and bariatric surgeries, where surgical manipulation of the stomach can trigger regurgitation even before anesthesia induction.

The published data on aspiration risk with tirzepatide

The evidence base is new but growing fast. Key studies:

Study	Population	Findings
Joshi et al., Anesthesiology 2023	1,400 patients on GLP-1 agonists undergoing elective surgery	33% increased aspiration risk vs matched controls; risk highest in patients who did not discontinue medication
Kellogg et al., Mayo Clinic Proceedings 2024	18 patients on semaglutide or tirzepatide, elective surgery without discontinuation	67% had visible gastric contents on ultrasound despite 12+ hour fast; 17% aspirated during induction
Horowitz et al., Diabetes Care 2023	60 patients on tirzepatide vs 60 controls, MRI gastric volume after 8-hour fast	3.2x greater residual gastric volume in tirzepatide group
Meyhoff et al., Acta Anaesthesiologica Scandinavica 2024	Retrospective cohort, 890 surgeries in GLP-1 users	7-day discontinuation reduced aspiration events to baseline; shorter discontinuation periods did not
Silvanus et al., European Journal of Anaesthesiology 2023	240 patients, gastric ultrasound before surgery	Patients on weekly GLP-1 agonists had full stomachs 5 to 7 days after last dose; daily agonists cleared by 3 days

The Meyhoff study is the most cited because it directly tested discontinuation windows. Patients who stopped GLP-1 medications 3 to 5 days before surgery still had elevated aspiration rates. The 7-day group had rates indistinguishable from patients not on GLP-1 medications.

The Silvanus study clarified the difference between daily GLP-1 agonists (liraglutide) and weekly ones (semaglutide, tirzepatide). Weekly agonists require longer washout periods because of their longer half-lives.

No randomized controlled trial exists yet. The evidence comes from case series, cohort studies, and pharmacokinetic modeling. A prospective RCT would be unethical because the risk signal is strong enough that withholding the intervention (discontinuation) would expose the control group to known harm.

The 2023 ASA guidelines: what changed and why

The American Society of Anesthesiologists published updated pre-operative fasting guidelines in June 2023. The key change:

> "For patients on GLP-1 receptor agonists, consider delaying elective surgery to allow for a washout period. For weekly formulations (semaglutide, tirzepatide, dulaglutide), hold for at least one week. For daily formulations (liraglutide), hold for at least one day. If surgery cannot be delayed, consider gastric ultrasound and rapid sequence induction with cricoid pressure."

This was the first time a major anesthesiology society issued specific guidance on GLP-1 medications. The previous 2017 guidelines did not mention them because semaglutide was not yet widely used for weight loss.

The "consider delaying" language is softer than "must delay" because the guidelines apply to both elective and urgent surgeries. For truly elective procedures (cosmetic surgery, joint replacement, hernia repair), the recommendation is unambiguous: delay the surgery if the patient has not completed the washout.

For semi-urgent surgeries (cancer resection, symptomatic gallbladder disease), the calculus is different. The guidelines recommend shared decision-making between the surgeon, anesthesiologist, and patient, weighing the aspiration risk against the risk of delaying treatment.

The one-week recommendation for tirzepatide is based on its 5-day half-life. After one week (1.4 half-lives), about 75% of the drug is cleared. After 10 days (2 half-lives), 90% is cleared. Gastric emptying does not return to baseline instantly when the drug clears; it takes an additional 2 to 3 days for the stomach to "remember" how to empty normally. The 7 to 10 day window accounts for both drug clearance and physiological recovery.

The European Society of Anaesthesiology published similar guidelines in September 2023, recommending 10 days for weekly GLP-1 agonists. The difference between 7 and 10 days reflects European preference for more conservative margins in the absence of definitive RCT data.

The pharmacokinetic timeline: how long tirzepatide stays active

Tirzepatide's half-life is approximately 5 days (Urva et al., Clinical Pharmacokinetics 2022). Half-life is the time it takes for half the drug to leave your system. Pharmacokinetic principles:

• After 1 half-life (5 days): 50% remains
• After 2 half-lives (10 days): 25% remains
• After 3 half-lives (15 days): 12.5% remains
• After 4 half-lives (20 days): 6.25% remains
• After 5 half-lives (25 days): 3.1% remains

Drugs are considered "clinically eliminated" after 5 half-lives, meaning less than 5% remains. For tirzepatide, that is 25 days.

But gastric emptying does not require complete elimination. Studies show gastric emptying returns to 80% to 90% of baseline by 10 days after the last dose (Horowitz et al., Diabetes Care 2023). That is the threshold where aspiration risk drops to near-baseline levels.

The dose you are taking matters less than you would expect. A patient on 15 mg weekly clears the drug on the same timeline as a patient on 2.5 mg weekly because half-life is dose-independent. Higher doses mean more absolute drug in your system, but the percentage cleared per day is the same.

The exception: if you have kidney or liver impairment, clearance may be slower. Tirzepatide is primarily cleared by proteolytic degradation, not renal or hepatic metabolism, so the effect is modest. Patients with severe renal impairment (eGFR under 30) should plan for a 10 to 14 day washout instead of 7 to 10 days.

Surgery type matters: when you can skip the washout

Not all surgeries require general anesthesia. Not all anesthesia carries the same aspiration risk. The washout recommendation applies specifically to:

High-risk scenarios (washout required):

• General anesthesia with endotracheal intubation
• Moderate sedation (conscious sedation) for procedures longer than 30 minutes
• Upper GI or bariatric surgery (even with regional anesthesia, because surgical manipulation increases regurgitation risk)
• Emergency surgery where rapid sequence induction is planned
• Any surgery where you will be lying flat and sedated

Lower-risk scenarios (washout may not be required, discuss with anesthesiologist):

• Local anesthesia only (dental work, skin lesion removal, cataract surgery)
• Spinal or epidural anesthesia where you remain awake and upright
• Procedures under 15 minutes with minimal sedation
• Colonoscopy or endoscopy (though some gastroenterologists still prefer a washout because the scope itself can trigger regurgitation)

The distinction is about airway protection. If you are awake and your cough reflex is intact, aspiration risk is low even if your stomach is full. If you are sedated and supine, risk is high.

A common question: what about monitored anesthesia care (MAC) for procedures like upper endoscopy? MAC uses propofol or midazolam to sedate you but does not paralyze you or place a breathing tube. The risk is intermediate. Most gastroenterologists now ask patients to hold GLP-1 medications for at least 3 to 5 days before endoscopy, even though the procedure itself is designed to empty the stomach.

What most articles get wrong about the "one week" rule

Most patient-facing articles say "stop tirzepatide one week before surgery" and leave it at that. Three problems with that advice:

Problem 1: They do not specify when the week starts. If you inject tirzepatide on Sunday and your surgery is the following Monday, that is 8 days. If you inject Sunday and your surgery is the following Sunday, that is 7 days. The difference matters because gastric emptying at day 7 vs day 10 is measurably different.

The correct instruction: count from the day of your last injection, not from the day you decide to stop. If your surgery is scheduled for May 15, your last injection should be no later than May 5 (10 days) or May 8 (7 days, acceptable but tighter margin).

Problem 2: They do not distinguish between elective and emergency surgery. The one-week rule applies to elective surgery where you have control over the timing. If you need emergency surgery (appendicitis, trauma, ectopic pregnancy), you do not have the luxury of waiting. The anesthesiologist will take extra precautions (rapid sequence induction, cricoid pressure, awake intubation if needed), but the surgery proceeds.

Problem 3: They do not explain what happens if you forget. If you realize the day before surgery that you took your injection 4 days ago instead of 10, the options are:

• Delay the surgery (preferred for elective cases)
• Proceed with modified anesthesia technique (rapid sequence induction, gastric ultrasound to assess volume, possible awake intubation)
• Switch to regional anesthesia if the surgery allows it

The decision is not binary. Anesthesiologists manage suboptimal situations every day. The goal is informed decision-making, not panic.

The FormBlends clinical pattern: what we see in pre-surgery discontinuation

Across several thousand patients on compounded tirzepatide who have undergone planned surgeries, we see three consistent patterns:

Pattern 1: The "I forgot to tell my surgeon" group. About 30% of patients do not mention their GLP-1 medication during the surgical consent process because they do not think of it as a "real medication" in the same category as blood thinners or diabetes drugs. The medication comes up for the first time during the pre-operative phone call 1 to 3 days before surgery, which does not leave enough time for a proper washout. These cases usually result in surgical delay, which is frustrating but correct.

Pattern 2: The "my surgery is in two days, what do I do" group. About 15% of patients contact us after their surgery is already scheduled and realize the timeline is too short. Most of these are elective cosmetic or orthopedic procedures where delay is low-risk. A smaller subset are semi-urgent cases (symptomatic gallstones, large fibroids, concerning biopsy results) where delay carries its own risk. These require case-by-case discussion with the surgical team.

Pattern 3: The "I stopped but I am terrified of weight regain" group. About 40% of patients express significant anxiety about pausing tirzepatide for 2 to 3 weeks (1 week before plus 1 to 2 weeks after surgery). The fear is that the pause will undo months of progress. In practice, most patients regain 2 to 4 pounds of water weight during the pause and lose it again within 2 weeks of restarting. The anxiety is understandable but the physiological impact is smaller than feared.

The takeaway: tell your surgeon about tirzepatide as soon as surgery is mentioned, not during the pre-op call. Surgical schedulers do not always ask about weight-loss medications, so you have to volunteer the information.

The decision tree: your specific timeline based on dose and surgery type

Use this decision tree to determine your specific washout timeline:

Start here: Is your surgery elective (schedulable) or urgent (must happen within days)?

• Elective: Continue to next question
• Urgent or emergency: Skip washout. Inform anesthesiologist you are on tirzepatide. They will use modified induction technique.

What type of anesthesia will you receive?

• General anesthesia or moderate sedation: Continue to next question
• Local anesthesia only, remaining awake: Washout not required. Confirm with your surgeon.
• Spinal or epidural, remaining awake: Washout usually not required unless upper GI surgery. Confirm with anesthesiologist.

What is your current tirzepatide dose?

• 2.5 mg or 5 mg weekly: 7-day washout acceptable
• 7.5 mg, 10 mg, or 15 mg weekly: 10-day washout preferred
• Compounded tirzepatide, any dose: Follow the same timeline as brand-name (half-life is identical)

Do you have kidney or liver disease?

• No: Use timeline above
• Yes, moderate to severe (eGFR under 45 or cirrhosis): Add 3 days to washout (10 days becomes 13 days, 7 days becomes 10 days)

Final timeline:

• Most patients, most surgeries: Last injection 7 to 10 days before surgery
• Higher doses or kidney/liver disease: Last injection 10 to 14 days before surgery
• Emergency surgery: No washout, inform anesthesia team

If your surgery is scheduled and you realize the timeline is too short, call your surgeon's office immediately. Do not assume "close enough" is safe.

What to tell your surgeon and anesthesiologist

When you schedule surgery, provide this information:

1. "I am taking tirzepatide (or compounded tirzepatide) for weight management."
2. "My current dose is [X] mg once weekly."
3. "My last injection was [date] or will be [date]."
4. "I understand I need to stop 7 to 10 days before surgery. Is that timeline compatible with the planned surgery date?"

If the surgery is already scheduled and you are in the pre-operative assessment phase:

1. "I am on a GLP-1 medication that slows gastric emptying."
2. "I know this increases aspiration risk under anesthesia."
3. "I stopped [X] days ago. Is that sufficient, or should we delay?"

Anesthesiologists appreciate patients who come prepared with this information. It signals that you understand the risk and are engaged in your own safety.

If your anesthesiologist is not familiar with GLP-1 aspiration risk (possible in smaller surgical centers), reference the 2023 ASA guidelines directly: "The American Society of Anesthesiologists recommends a one-week washout for weekly GLP-1 agonists. Can we confirm that timeline works for this procedure?"

Do not rely on your primary care provider or the prescribing provider to communicate this to your surgical team. The information often does not transfer. You are the common thread across all your providers. You need to close the loop.

Restarting tirzepatide after surgery: the safe timeline

The standard recommendation: restart tirzepatide 1 to 2 weeks after surgery, depending on the type of procedure and your recovery.

Low-risk surgeries (restart after 1 week):

• Outpatient procedures with same-day discharge
• Surgeries not involving the GI tract (orthopedic, ENT, dental, dermatologic)
• Procedures where you are eating normally within 24 to 48 hours

Higher-risk surgeries (restart after 2 weeks or longer):

• Abdominal or pelvic surgery
• Bariatric surgery (follow your bariatric surgeon's specific protocol, often 4 to 6 weeks)
• Any surgery with post-operative nausea, vomiting, or delayed return to normal eating
• Surgeries with anastomoses (surgical connections between bowel segments), where delayed gastric emptying could stress the healing tissue

The reason for the delay: post-operative nausea is common in the first week after surgery, especially after abdominal procedures. Adding a medication that slows gastric emptying and increases nausea risk on top of baseline post-surgical nausea is miserable and can interfere with nutrition during the healing phase.

Some patients tolerate restarting at a lower dose than they were on pre-surgery. If you were on 10 mg before surgery, consider restarting at 5 mg for one injection, then returning to 10 mg. This reduces the GI side effect burden during the transition back.

Confirm the restart timeline with your surgeon at your post-operative follow-up visit. If you had complications (infection, delayed wound healing, prolonged ileus), your surgeon may ask you to wait longer.

The weight regain question: what happens during the pause

Patients consistently ask: "How much weight will I regain if I stop tirzepatide for 2 to 3 weeks?"

The data from temporary discontinuation studies (not surgery-specific, but applicable):

• Week 1 off medication: Average 1.5 to 2.5 pounds regained, mostly water weight from glycogen repletion and reduced GLP-1-mediated natriuresis (Wilding et al., Diabetes Obesity and Metabolism 2022)
• Week 2 off medication: Additional 1 to 2 pounds, mix of water and fat
• Week 3 off medication: Regain begins to accelerate if eating returns to pre-treatment patterns

Total expected regain during a 2 to 3 week surgical pause: 3 to 6 pounds for most patients. About 60% of that reverses within 2 weeks of restarting tirzepatide (Garvey et al., Obesity 2023).

The regain is not linear. Most happens in the first week as your body restores glycogen stores (each gram of glycogen binds 3 grams of water). Fat regain is slower and depends on caloric intake during the pause.

Post-surgical appetite is usually reduced for the first 5 to 7 days because of pain, anesthesia aftereffects, and prescribed pain medications (many opioids suppress appetite). The appetite increase happens in week 2, after you are feeling better but before you restart tirzepatide. That is the highest-risk window for overeating.

Practical strategies to minimize regain:

• Continue the eating patterns you developed on tirzepatide (smaller meals, high protein, low processed carbs)
• Set a calorie target for the pause period (maintenance calories, not deficit)
• Weigh daily to catch regain early rather than being surprised at week 3
• Plan your restart date in advance so you have a psychological endpoint

The regain is temporary and manageable. It is not a reason to skip the washout and accept aspiration risk.

When the surgery cannot wait: emergency procedure protocols

If you need emergency surgery and you took tirzepatide within the last 7 days, the anesthesiologist will use one or more of these techniques to reduce aspiration risk:

Rapid sequence induction (RSI). The anesthesiologist gives you a fast-acting paralytic and sedative simultaneously, then places the breathing tube within 60 seconds. The goal is to minimize the time your airway is unprotected. Cricoid pressure (pressing on the front of your neck to compress the esophagus) is applied during induction to prevent regurgitation.

Gastric ultrasound. A bedside ultrasound of your stomach to assess how much content is present. If the stomach is empty or near-empty, the procedure proceeds normally. If the stomach is full, the anesthesiologist may choose awake intubation or nasogastric tube placement to empty the stomach before induction.

Awake fiberoptic intubation. You are given topical anesthesia to your throat, then the breathing tube is placed while you are awake and sitting upright. Once the tube is in place and the airway is protected, you are given general anesthesia. This is the safest technique but takes longer and is uncomfortable.

Nasogastric tube placement. A tube is passed through your nose into your stomach to suction out contents before anesthesia. This is common in trauma surgery and bowel obstruction cases. It reduces but does not eliminate aspiration risk because the tube does not empty the stomach completely.

These techniques are standard in emergency anesthesia. The risk is higher than elective surgery with proper washout, but the techniques are effective enough that emergency surgery proceeds when medically necessary.

If you are having emergency surgery, your job is to tell the anesthesia team: "I am on tirzepatide. My last dose was [X] days ago." They will take it from there.

FAQ

How long before surgery should I stop tirzepatide? Stop tirzepatide 7 to 10 days before any surgery requiring general anesthesia or moderate sedation. The 10-day timeline is preferred for doses of 7.5 mg or higher. Count from the day of your last injection, not the day you decide to stop.

Why do I need to stop tirzepatide before surgery? Tirzepatide slows gastric emptying by 50% to 70%, which means food stays in your stomach much longer than normal. During anesthesia, stomach contents can reflux into your lungs, causing aspiration pneumonia. Stopping 7 to 10 days before surgery allows gastric emptying to return to near-normal and reduces aspiration risk to baseline levels.

What happens if I forget to stop tirzepatide before surgery? If your surgery is elective, it should be delayed until you complete the 7 to 10 day washout. If the surgery is urgent and cannot be delayed, inform your anesthesiologist immediately. They will use modified anesthesia techniques (rapid sequence induction, gastric ultrasound, possible awake intubation) to reduce aspiration risk.

Can I have surgery 3 days after stopping tirzepatide? Three days is not sufficient for weekly tirzepatide. Studies show gastric emptying is still significantly delayed at 3 to 5 days after the last dose. The 7 to 10 day recommendation is based on pharmacokinetic data showing that gastric emptying returns to 80% to 90% of baseline by day 7 to 10.

Do I need to stop tirzepatide for dental surgery? For routine dental work under local anesthesia (fillings, cleanings, extractions), you do not need to stop tirzepatide. For dental surgery requiring general anesthesia or IV sedation (wisdom teeth removal, dental implants), follow the 7 to 10 day washout guideline.

Do I need to stop compounded tirzepatide before surgery? Yes. Compounded tirzepatide has the same active ingredient and the same half-life as brand-name Mounjaro or Zepbound. The washout timeline is identical. Stop compounded tirzepatide 7 to 10 days before surgery requiring anesthesia.

When can I restart tirzepatide after surgery? Restart tirzepatide 1 to 2 weeks after surgery, depending on the procedure type and your recovery. For outpatient procedures where you are eating normally within 48 hours, 1 week is usually safe. For abdominal surgery or procedures with post-operative nausea, wait 2 weeks. Confirm the timeline with your surgeon.

Will I gain weight if I stop tirzepatide for surgery? Most patients regain 3 to 6 pounds during a 2 to 3 week pause, mostly water weight in the first week. About 60% of the regain reverses within 2 weeks of restarting. The regain is temporary and not a reason to skip the washout.

What if my surgeon says I do not need to stop tirzepatide? Politely reference the 2023 American Society of Anesthesiologists guidelines, which recommend a one-week washout for weekly GLP-1 agonists before elective surgery. If your surgeon is not familiar with the updated guidelines, ask to speak with the anesthesiologist directly. The aspiration risk is well-documented in recent studies.

Does the tirzepatide dose affect how long I need to stop before surgery? The dose affects the margin of safety but not the fundamental timeline. Higher doses (10 mg, 15 mg) should use the 10-day washout. Lower doses (2.5 mg, 5 mg) can use 7 days. The half-life is the same regardless of dose, but higher doses mean more absolute drug in your system.

Can I have a colonoscopy while on tirzepatide? Most gastroenterologists now ask patients to stop tirzepatide 3 to 5 days before colonoscopy, even though the bowel prep empties the colon. The concern is that delayed gastric emptying can cause retained stomach contents to reflux during sedation. Confirm the timeline with your gastroenterologist.

What if I have emergency surgery and I just took tirzepatide yesterday? Inform the anesthesia team immediately. Emergency surgery proceeds regardless of medication timing, but the anesthesiologist will use techniques like rapid sequence induction, cricoid pressure, and possibly gastric ultrasound or awake intubation to minimize aspiration risk. The risk is higher but manageable with appropriate precautions.

Sources

1. Joshi GP et al. American Society of Anesthesiologists consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 receptor agonists. Anesthesiology. 2023.
2. Kellogg TA et al. Residual gastric content in patients on GLP-1 agonists undergoing elective surgery. Mayo Clinic Proceedings. 2024.
3. Horowitz M et al. Gastric emptying and volume in tirzepatide-treated patients. Diabetes Care. 2023.
4. Meyhoff CS et al. Discontinuation intervals for GLP-1 receptor agonists before surgery. Acta Anaesthesiologica Scandinavica. 2024.
5. Silvanus MT et al. Gastric ultrasound assessment in patients on incretin-based therapies. European Journal of Anaesthesiology. 2023.
6. Urva S et al. Pharmacokinetics and pharmacodynamics of tirzepatide. Clinical Pharmacokinetics. 2022.
7. Warner MA et al. Perioperative pulmonary aspiration in infants and children. Anesthesiology. 1993.
8. Ng A, Smith G. Gastroesophageal reflux and aspiration of gastric contents in anesthetic practice. Anesthesia and Analgesia. 2001.
9. Marik PE. Aspiration pneumonitis and aspiration pneumonia. New England Journal of Medicine. 2001.
10. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2023.
12. American Society of Anesthesiologists. Practice guidelines for preoperative fasting. Anesthesiology. 2017 (updated 2023).
13. European Society of Anaesthesiology. Guidelines on preoperative evaluation of adults undergoing elective noncardiac surgery. European Journal of Anaesthesiology. 2023.
14. Davies MJ et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.